title: Cell-permeable, mitochondrial-targeted, peptide antioxidants.
abstract: Cellular oxidative injury has been implicated in aging and a wide array of clinical disorders including ischemia-reperfusion injury; neurodegenerative diseases; diabetes; inflammatory diseases such as atherosclerosis, arthritis, and hepatitis; and drug-induced toxicity. However, available antioxidants have not proven to be particularly effective against many of these disorders. A possibility is that some of the antioxidants do not reach the relevant sites of free radical generation, especially if mitochondria are the primary source of reactive oxygen species (ROS). The SS (Szeto-Schiller) peptide antioxidants represent a novel approach with targeted delivery of antioxidants to the inner mitochondrial membrane. The structural motif of these SS peptides centers on alternating aromatic residues and basic amino acids (aromatic-cationic peptides). These SS peptides can scavenge hydrogen peroxide and peroxynitrite and inhibit lipid peroxidation. Their antioxidant action can be attributed to the tyrosine or dimethyltyrosine residue. By reducing mitochondrial ROS, these peptides inhibit mitochondrial permeability transition and cytochrome c release, thus preventing oxidant-induced cell death. Because these peptides concentrate >1000-fold in the inner mitochondrial membrane, they prevent oxidative cell death with EC50 in the nM range. Preclinical studies support their potential use for ischemia-reperfusion injury and neurodegenerative disorders. Although peptides have often been considered to be poor drug candidates, these small peptides have excellent "druggable" properties, making them promising agents for many diseases with unmet needs.
authors.affiliation: Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA. hhszeto@med.cornell.edu
authors.forename: Hazel H
authors.initials: HH
authors.lastname: Szeto
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002463:Cell Membrane Permeability / Q000502:physiology*; D006801:Humans; D008928:Mitochondria / Q000378:metabolism*; D008954:Models, Biological; D018384:Oxidative Stress; D010455:Peptides / Q000493:pharmacokinetics*; D026361:Reactive Nitrogen Species / Q000493:pharmacokinetics / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000493:pharmacokinetics / Q000494:pharmacology*; D015427:Reperfusion Injury / Q000503:physiopathology
chemical_list: D000975:Antioxidants; D010455:Peptides; D026361:Reactive Nitrogen Species; D017382:Reactive Oxygen Species